Pages that link to "Q33801821"
Jump to navigation
Jump to search
The following pages link to Drug interactions with new and investigational antiretrovirals (Q33801821):
Displaying 37 items.
- A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice (Q27692040) (← links)
- Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis (Q28534412) (← links)
- Switch from Enfuvirtide to Raltegravir Lowers Plasma Concentrations of Darunavir and Tipranavir: a Pharmacokinetic Substudy of the EASIER-ANRS 138 Trial (Q35065925) (← links)
- Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1 (Q35557235) (← links)
- Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects (Q35689388) (← links)
- Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals (Q36018556) (← links)
- idTarget: a web server for identifying protein targets of small chemical molecules with robust scoring functions and a divide-and-conquer docking approach (Q36088437) (← links)
- Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir (Q36290561) (← links)
- PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein (Q36675727) (← links)
- Effects of etravirine on the pharmacokinetics and pharmacodynamics of warfarin in rats (Q36756991) (← links)
- Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management (Q36900535) (← links)
- Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. (Q37113947) (← links)
- Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action (Q37650120) (← links)
- Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection (Q37762248) (← links)
- Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges (Q37780220) (← links)
- Drug interactions of new antiretroviral drugs (Q37826265) (← links)
- Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients (Q37845854) (← links)
- Antihypertensive drugs in patients treated with antiretrovirals (Q38006933) (← links)
- Safety of pharmacoenhancers for HIV therapy (Q38057371) (← links)
- Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group (Q38673153) (← links)
- Vaginal ecosystem modeling of growth patterns of anaerobic bacteria in microaerophilic conditions (Q38812851) (← links)
- Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics (Q38882614) (← links)
- Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection (Q39154839) (← links)
- Interaction potential of etravirine with drug transporters assessed in vitro (Q39614865) (← links)
- Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO. (Q40722214) (← links)
- Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals (Q42215539) (← links)
- Expression of membrane drug efflux transporters in the sigmoid colon of HIV-infected and uninfected men. (Q42283655) (← links)
- Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. (Q42491474) (← links)
- Novel findings about management of gastric cancer: a summary from 10th IGCC. (Q42751821) (← links)
- Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. (Q42873289) (← links)
- A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients (Q44881280) (← links)
- MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption. (Q48145638) (← links)
- Drug Interactions Should Be Evaluated in Patients (Q51897591) (← links)
- Antimicrobial Agents (Q57549163) (← links)
- Drug interactions with new and investigational antiretrovirals (Q82287218) (← links)
- A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs (Q82466696) (← links)
- Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol (Q94559419) (← links)